An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer

Published:2015-09-29 Issue:12 Volume:16 Page:1720-1725
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Roviello Giandomenico,Francini Edoardo,Perrella Armando,Laera Letizia,Mazzei Maria Antonietta,Guerrini Susanna,Petrioli Roberto

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/15384047.2015.1095410

Reference20 articles.

1. Estimating the world cancer burden: Globocan 2000

2. Targeting the Epigenome for the Treatment and Prevention of Lung Cancer

3. Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation

4. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

5. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review;Molecular and Clinical Oncology;2018-06-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3